Reading between the lines: Direct-to-consumer advertising of genetic testing in the USA

References

• T. Frank. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal of Clinical Oncology. 16: 1998; 2417–2425.
   PubMed Web of Science ®Google Scholar
• L. Verhoog. Survival and tumor characteristics of breastcancer patients with germline mutations of BRCA1. Lancet. 351: 1998; 316–321.
   PubMed Web of Science ®Google Scholar
• D. Easton, D. Ford, D. Bishop. Breast and ovarian cancer incidence in BRCA1 mutation carriers. American Journal of Human Genetics. 56: 1995; 265–271.
   PubMed Web of Science ®Google Scholar
• D. Schrag. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA. 283: 2000; 617–624.
   PubMed Web of Science ®Google Scholar
• T. Frank. Sequence Analysis of BRCA1 and BRCA2. Journal of Clinical Oncology. 16: 1998; 2417.
   PubMed Web of Science ®Google Scholar
• J. Struewing. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. NEJM. 336: 1997; 1401–1408.
   PubMed Web of Science ®Google Scholar
• E. Claus. The genetic attributable risk of breast and ovarian cancer. Cancer. 77: 1996; 2318–2324.
   PubMed Web of Science ®Google Scholar
• D. Easton. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. America Journal of Human Genetics. 52: 1993; 678–701.
   PubMed Web of Science ®Google Scholar
• S. Narod. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. American Journal of Human Genetics. 56: 1995; 254–264.
   PubMed Web of Science ®Google Scholar
• F.J. Couch. BRCA1 Mutations in women attending clinics that evaluate the risk of breast cancer. NEJM. 336: 1997; 1409–1415.
   PubMed Web of Science ®Google Scholar
• T. Frank. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2. Disease Markers. 15: 1999; 89–92.
   Web of Science ®Google Scholar
• L. Brody, B. Biesecker. Breast cancer: the high-risk mutations. Hospital Practice. 1997; 59–80.
   Web of Science ®Google Scholar
• P. Rosen, S. Groshen, D. Kinne. Prognosis in T2NoMo Stage I breast carcinoma: a 20 year follow-up study. Journal of Clinical Oncology. 9: 1991; 1650–1661.
   PubMed Web of Science ®Google Scholar
• P. Rosen. Contralateral breast carcinoma: an assessment of risk and prognosis in Stage I (T1N0M0) and Stage II (T1N1M0) patients with 20 year follow-up. Surgery. 106: 1989; 904–910.
   PubMed Web of Science ®Google Scholar
• A. Whittemore, G. Gong, J. Intyre. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based control studies of ovarian cancer. American Journal of Human Genetics. 60: 1997; 496–504.
   PubMed Web of Science ®Google Scholar
• D.A. Haber. Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum. Journal of Clinical Oncology. 17: 1999; 3367–3369.
   Web of Science ®Google Scholar
• L. Verhoog. Survival and tumor characteristics. Lancet. 351: 1998; 316–321.
   PubMed Web of Science ®Google Scholar
• W. Burke. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. JAMA. 277: 1997; 997–1003.
   PubMed Web of Science ®Google Scholar
• National Conference of State Legislatures, State Genetic Laws Reference Table. 14 February 2000 http://www.ncsl.org/programs/employ/Genetics/sg-law.htm
   Google Scholar
• Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 110 Stat. 1936. 1996. (codified as amended in scattered sections of 18 U.S.C.; 26 U.S.C.; 29 U.S.C.; 42 U.S.C.).
   Google Scholar
• 66 Fed. Reg. 12434. 26 February 2001
   Google Scholar
• C. Lerman. Controlled trial of pretest education approaches to enhance informed decisionmaking for BRCA1 gene testing. Journal of the National Cancer Institute. 89: 1997; 148–157.
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology Statement of American Society of Clinical Oncology. Genetic Testing for Cancer Susceptibility. Journal of Clinical Oncology. 14: 1996; 1730–1736.
   Google Scholar
• J.H. Tanne. Direct to consumer drug advertising is billion dollar business in US. BMJ. 319: 1999; 805.
   Google Scholar
• K.N. Reeves. Direct-to-consumer broadcast advertising: empowering the consumer or manipulating a vulnerable population?. Food Drug Law Journal. 53: 1998; 661–679.
   PubMed Web of Science ®Google Scholar
• M.F. Hollon. Direct-toconsumer marketing of prescription drugs: creating consumer demand. JAMA. 281: 1999; 382–384.
   PubMed Web of Science ®Google Scholar